<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551147</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-6950POU005</org_study_id>
    <nct_id>NCT01551147</nct_id>
  </id_info>
  <brief_title>A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Three-way Crossover Study to Compare the Safety and Efficacy of 8 Days of Therapy With ONO-6950 Versus Placebo and Montelukast (Singulair®) on Asthmatic Responses and Airway Hypersensitivity Following Allergen Challenge in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharma USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives are&#xD;
&#xD;
        -  to determine the effect of ONO-6950 200 mg QD versus placebo administered for 8 days on&#xD;
           early asthmatic response (EAR) and late asthmatic response (LAR) induced by inhaled&#xD;
           allergen&#xD;
&#xD;
        -  to determine the safety and tolerability of ONO-6950 200 mg QD administered for 8 days&#xD;
           in patients with asthma&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  to compare the effect of ONO-6950 versus montelukast on the % decrease of FEV1 following&#xD;
           allergen exposure, and&#xD;
&#xD;
        -  to determine the effect of ONO-6950 versus placebo and montelukast on allergen-induced&#xD;
           airway hyperresponsiveness (AHR) as measured by methacholine challenge&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will examine if ONO-6950 could alleviate EAR and LAR caused by an allergen&#xD;
      challenge in subjects with asthma. Patients will be required to have EAR and LAR after&#xD;
      standardized allergen challenges during the screening. Eligible patients will complete a&#xD;
      randomized, double-blind, three-way crossover study. During each of three evaluation periods,&#xD;
      patients will be administered either 200 mg ONO-6950, 10 mg Montelukast, or placebo for 8&#xD;
      days. Each evaluation period will occur over 8 days and will include various assessments&#xD;
      following allergen challenge and methacholine challenge. The study does not require an&#xD;
      overnight stay at the clinical research center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Asthmatic Response (3-7 hours after allergen challenge) as measured by the AUC in FEV1</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Early Asthmatic Response as measured by the AUC in FEV1</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Late Asthmatic Response as measured by the Maximum Fall in FEV1</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Early Asthmatic Response as measured by the Maximum Fall in FEV1</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in PC20 pre-post treatment as measured by methacholine challenge</measure>
    <time_frame>Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in PC20 pre-post allergen challenge as measured by methacholine challenge</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Experimental 200 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-6950</intervention_name>
    <description>200 mg QD for 8 days</description>
    <arm_group_label>Experimental 200 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>10 mg Montelukast QD for 8 days</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both genders, between 18 to 60 years of age, with bronchial asthma&#xD;
             symptoms for at least 6 months&#xD;
&#xD;
          -  Patients with FEV1 ≥ 70% of predicted after withholding short-acting β agonists for at&#xD;
             least 8 hours prior to testing&#xD;
&#xD;
          -  Screening allergen challenge demonstrates that the patient experiences both an early&#xD;
             and late asthmatic response&#xD;
&#xD;
          -  Sensitivity to methacholine resulting in a ≥ 20% fall in FEV1 (PC20 methacholine)&#xD;
&#xD;
          -  Non-smokers with free from the usage of nicotine-containing products at least for a&#xD;
             year prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of life-threatening asthma, respiratory tract infection and/or&#xD;
             exacerbation of asthma within 6 weeks prior to the first screening visit&#xD;
&#xD;
          -  Past or present disorders and diseases including, but are not limited to,&#xD;
             cardiovascular, malignancy, hepatic, renal, hematological, neurological, psychiatric,&#xD;
             endocrine, or pulmonary other than asthma&#xD;
&#xD;
          -  Significant safety laboratory, ECG, or vital sign abnormalities that would place the&#xD;
             patient at undue disk during the study procedures&#xD;
&#xD;
          -  History of clinically significant multiple drug or food allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ono Pharma USA, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver Clinical Site 530</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calgary Clinical Site 540</name>
      <address>
        <city>Alberta</city>
        <zip>T2N4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Clinical Site 550</name>
      <address>
        <city>Ontario</city>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quebec Clinical Site 510</name>
      <address>
        <city>Quebec City</city>
        <zip>G1V4GS</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Clinical Site 520</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7N0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <last_update_submitted>April 29, 2013</last_update_submitted>
  <last_update_submitted_qc>April 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>ONO-6950</keyword>
  <keyword>asthma in adult patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

